This could be a blockbuster drug from GSK – RSVPreF3 OA – Respiratory

Viewing 1 post (of 1 total)
  • Author
  • #24936

    RSV is a very contagious seasonal virus that impacts the respiratory tract and lungs. Unsurprisingly, RSV is typically accompanied by a congested or runny nose, a cough, sneezing, and fever.

    While anyone can experience a severe case of the virus, children under age five and adults over 65 with weakened immune systems or co-morbidities, such as heart or lung disease, are most at risk. In fact, RSV hospitalizes 58,000 to 80,000 children under five years old and 60,000 to 160,000 adults 65 years and older in the United States each year.

    GSK enrolled nearly 25,000 patients at least 60 years of age in its phase 3 clinical trial to receive either its RSV vaccine candidate, called RSVPreF3 OA, or placebo before the RSV season. At the median follow-up of 6.7 months (the approximate length of a full RSV season), overall vaccine efficacy was 82.6% in the vaccine group compared to the placebo group. With a 94.1% efficacy rate in protecting against severe RSV-related lower respiratory tract disease, the vaccine was quite potent.


Viewing 1 post (of 1 total)
  • You must be logged in to reply to this topic.